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Abstract
I am interested in the development of the nervous system, especially since during
development nerves grow and extend, but in adults, they do not regenerate if damaged.
We are specifically interested in the molecules that guide nerves to the correct target
during their development. Lysophosphatidic acid (LPA) is a bioactive molecule that has
been shown to play a role in neural development. LPA, through repeated studies, has
been shown to stop neurons from growing by causing a physical change in a neuron’s
growth cone (a structure used for navigation and growth). Recently, a novel set of
genes, called PRGs, have been demonstrated to interact with LPA and LPA receptors.
However, interaction between PRGs and LPA is not well understood. Thus, I
investigated the role of PRG and LPA in neuronal development, focused on the visual
system in chicken embryos. During this study I determined expression of PRG genes in
the developing chicken eye using RT-PCR. Then I designed target sequences for
mutation of chicken PRG gene using CRISPR and cloned targeting guides. I designed
six guide RNAs (gRNAs) to target one specific PRG-2 gene determined by the
expression studies. I then evaluated these gRNA constructs to determine if they
efficiently mutate PRG-2 in cells. This project then required delivery of my gRNA DNA
constructs to embryonic chicken eyes via electroporation to induce mutations in the
retinal ganglion cells (RGCs) of the eye that compose the optic nerve which I optimized.
I then overexpressed PRG-2/GFP fusion protein in chicken fibroblast cells to confirm my
construct would be a candidate for overexpression in chicken retina.
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Chapter One
Literature Review of PRG
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Neurological Disease, Central Nervous System Injury
The central nervous system (CNS) in vertebrates is a highly organized system
composed of millions of cells (Waxenbaum et al. 2021). The CNS is composed of two
parts: the brain and the spinal cord. All other neurons extending from the spinal cord to
the rest of the body make up the Peripheral Nervous System (PNS). These two systems
coordinate all the biochemical interactions that occur in an organism (Waxenbaum et al.
2021). Understanding how these vast numbers of cells differentiate, grow, communicate,
and organize, ultimately developing into the nervous system, is a central focus in the
foundations of neuroscience. One reason neuroscientists focus on nervous system
development is the hope of finding a cure for neuropathological diseases—most
neuropathological diseases affecting the CNS result in neurological damage. Depending
on the system involved, the damage could be either transient, healing over time, or
permanent, resulting in neuronal cell loss.
The PNS of most species exhibits regenerative abilities. When injured or
damaged, neuronal cells regenerate and reestablish functionality. Conversely, at least in
humans, the CNS does not "naturally" demonstrate this capability (Mietto et al. 2015).
Multiple neurodegenerative diseases affect the central nervous system, including
Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS),
multiple sclerosis (MS), Huntington's disease, and multiple system atrophy, which all
result in lasting damage to the CNS (Mietto et al. 2015). This damage in mammals over
time leads to neuronal loss or dysfunction; however, in a wide range of lower animals,
this neuronal loss can be restored through a regenerative mechanism. The PNS and
CNS, in most species, can correct the damage done by pathological insult (Richardson
et al. 1980). However, in most vertebrates like humans, injured neuronal cells in the
CNS demonstrate anti-regenerative properties that prevent them from restoring functions
and reestablishing connections after injury (Schwab and Caroni 1988). This contrasts
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with the PNS neurons, which regenerate when injured, eventually restoring function over
time (Huebner and Strittmatter 2009). Understanding how the CNS develops and
organizes would explain how these inhibitory qualities are expressed and ways to
overcome their inhibition. Ultimately, overcoming the inhibition of nerve regeneration
would give neuroscientists a possible therapeutic tool for treating neuropathological
diseases affecting the CNS.
Central Nervous System Development
The CNS must develop in a specific way to successfully manage an organism's
functions. The developing cells of the CNS extend axons that navigate through the
environment by sending and receiving information through chemical stimuli (Figure 1).
Axons use a chemo-sensitive structure called a growth cone to respond to extracellular
chemical stimuli and navigate to their appropriate targets (Tessier-Lavigne and
Goodman 1996). The CNS develops its neuronal circuitry by extending axons through a
multitude of tissues. Axons must navigate through dense cellular regions to specific
target areas to form this circuitry, including synaptic connections with other neurons. The
vast number of cells, axons, and connections make investigating development difficult.
Therefore, neuroscientists often use the visual system to model nerve growth in CNS
development because of its particular topographical organization and easy accessibility
(Erskine and Herrera 2007). In the visual system, retinal ganglion cells (RGCs) in the
eye project axons toward the brain in a highly reproducible pattern (Huberman et al.
2003), suggesting axons use guidance cues to find their way in their visual map
formation. These guidance cues are all integrated by the growth cone.
The growth cone is composed of an actin network and associated microfilaments
at its distal end and at its proximal end, microtubules made of tubulin. Growth cones are
located at the end of growing axons and are lined with receptors that allow the cell to
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respond to molecular cues in the extracellular environment (Huberman et al. 2003).
When activated, the receptors lining the growth cone lead to a cascade of signaling
pathways, such as Rho and ROCK, that results in the tubulin and actin polymerizing at
the distal tip to generate microtubules and microfilaments respectively (Fincher et al.
2014). Growth cones are activated by axon guidance molecules that promote axonal
growth toward a target or repulse axons away from a target. Axon guidance molecules
can be localized originating from surrounding or originating from distance sources act
over long distances to determine the routes developing axons follow to their targets
(Tessier-Lavigne and Goodman 1996). Several known axon guidance molecules include
netrins, slits, semaphorins, and ephrins. Recently, lysophosphatidic acid (LPA) has been
theorized to be an axon guidance molecule (Birgbauer 2021; Birgbauer and Chun 2010;
Fincher et al. 2014)

Figure 1: Retinal ganglion cells (Black circle) extend axons (Black Line) through an
extracellular environment rich with guidance cues. These guidance cues can be
attractive such as Netrins (plus in blue) or repellant such as LPA (minus in grey). The
axon uses a special structure called a growth cone (Black projections) to interpret
guidance cues. The growth cone guides the axon to its destination in development by
responding to the extracellular environment using receptors.
Multiple types of guidance cues and receptors have been identified that direct the
projections taken during axonal development.
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Lysophosphatidic Acid Receptor-mediated Signaling
Lysophosphatidic acid (LPA) is a monoacyl-sn-glycerol-3-phosphate bioactive
lysophospholipid with a phosphoglycerol head and a single tail (Birgbauer 2021). It
belongs to a class of bioactive molecules, each with differing fatty acid chain lengths and
degrees of saturation. LPA is expressed by many tissues and is produced by two
pathways: hydrolysis of phosphatidic acid (PA) by phospholipase A1 and A2 or cleavage
of lysophosphatidylcholine (LPC) by autotaxin. LPA receptors are highly expressed in
the brain. LPA has been found to play a role in neural development by inducing growth
cone collapse and neurite retraction via a receptor-mediated signaling response
(Fukushima et al. 2001). Multiple receptors have been hypothesized to induce this cell
signaling, including the family of six G coupled protein receptor (GPCR) LPAR 1-6,
which couple with multiple G-proteins (G12/13, Gi, Gq, Gs). Although LPARs have been
well characterized, their specific effect on axonal growth is poorly understood due to
functional redundancy in their pathway activation (Birgbauer 2021). These activated
pathways generally result in microfilament and cytoskeletal rearrangements, which
provide the motility needed by neurons to navigate to specific targets. Previous research
showed that cultured RGC axon growth cones collapse dose-dependently when
exposed to LPA (Birgbauer and Chun 2010; Fincher et al. 2014). Incongruously, LPAreceptor knockout mice for some of the LPA receptors did not lead to significant
neuronal aberrations or inhibitory growth cone effects in retinal growth cones (Birgbauer
and Chun 2010). However, multiple studies have shown that LPA may be involved in
axon guidance in the brain and retina (Birgbauer 2021), which may suggest alternative
LPA-dependent signaling pathways independent of the classic GPCR. Thus, significant
work is still needed to classify LPA as a bona fide axon guidance molecule and to
identify its corresponding receptors.
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LPA is known to be enzymatically inactivated by lipid phosphate phosphatases
(LPPs), a superfamily of cell surface protein receptors. LPPs are characterized by six
transmembrane domains containing highly conserved enzymatically active domains
(Bräuer et al. 2003). Some members of the LPP superfamily, namely, LPP1-3 and splice
variant LPP1A, can degrade LPA (Alderton et al. 2001). A novel sub-family of
membrane-bound LPPs, plasticity-related genes (PRG1-5), was recently identified while
investigating brain plasticity mechanisms. Sequence alignments show homology
between PRGs and LPPs, specifically LPP1 (Brauer 2008). Interestingly, PRGs 1-5 are
all vertebrate-specific and offer varying expression patterns in brain tissue throughout
development. Overexpression of PRG-1 in neuronal cell lines protects developing axons
from LPA-induced neurite collapse (Bräuer et al. 2003). Additionally, PRG-1
overexpression increases the LPA degradation product monoacylglycerol (MAG) (Bräuer
et al. 2003). LPA is suggested to guide thalamic axons to the cortex of PRG-2 null mice
(Cheng et al. 2016). Furthermore, PRGs are linked to axonal growth, neurite shaft
protrusion in primary neurons, and dendritic spine formation (Yu et al. 2015). PRG is a
subfamily of transmembrane proteins that possibly have different or redundant modes of
action with LPA (Bräuer et al. 2003). The interaction between PRGs and LPAs is not well
understood.
Plasticity Related Genes
PRG-1 was the first in the family to be discovered while investigating the
mechanism by which the hippocampus typically develops and heals after injury in
humans (Bräuer et al. 2003). For instance, they found that when hippocampal axons
form the entorhinal cortex are transected, the remaining axons demonstrate regenerative
axon sprouting into denervated zones. While investigating the molecular mechanisms
responsible for this hippocampal plasticity, the protein receptor PRG-1 was found to
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have a distinct expression pattern starting at embryonic day 19 (E19). In parallel, axons
of the hippocampus grow from the entorhinal cortex at E19 in vivo. This expression and
parallel growth suggested that PRG-1 played a role in axonal development and
regenerative sprouting. Since its discovery, PRG-1 expression has been identified in the
cerebellar cortex, olfactory bulb, cerebral cortex, and caudate putamen (Tokumitsu et al.
2010). PRG has been observed in neuronal axons to facilitate lipid phosphate
degradation and fiber outgrowth in a repellent environment (Bräuer et al. 2003). Axons
(when grown in an LPA-rich environment) of younger E16 mice that lack PRG-1 will
undergo neurite retraction; however, older E19 mice axons that express PRG-1 grown in
the same environment resist this retraction in a dose-dependent manner. Interestingly,
after a lesion occurs in the hippocampus, PRG-1 is upregulated within 24 hours in
denervated areas (Bräuer et al. 2003). The behavior of axons with and without PRG-1
expression in the presence of LPA strengthened support for PRG-1’s involvement in
axonal guidance. In contrast, LPA-specific receptors LPA-1, LPA-2, and LPA-3 are also
expressed in developing neurons and could account for the observed neurite retraction
seen by Brauer et al. (2003). However, unlike PRG-1, there is no corresponding
difference in the expression pattern of LPA-specific receptors throughout E16-E19
development when LPA responses change. The lack of LPA-receptor regulation
suggests that the observed attenuation of neurite retraction results from only PRG-1 and
no other known LPA-specific receptors. Additionally, others have demonstrated that
PRG-1 can interfere with signal transduction through LPA interactions at the synaptic
cleft (Trimbuch et al. 2009). Trimbunch et al. (2009) observed that PRG-1 knockout mice
had a corresponding 50% reduction in the uptake of fluorescence-labeled LPA.
Extracellular LPA signaling is essential for CNS development and postmitotic neurons
provide an endogenous source for LPA (Fukushima et al. 2001). Others have shown
evidence that PRG-1 reduces available extracellular LPA, thus attenuating repulsive
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signaling (Trimbuch et al. 2009). Similarly, others have shown PRG-1 deletion or
mutation results in aberrant synaptic signaling within glutamatergic neurons due to
altered lipid processing (Liu et al. 2016; Schneider et al. 2018; Vogt et al. 2017). These
observations, in total, suggest that PRG-1 plays a pivotal in response to LPA and might
also be responsible for how the axon's growth cone responds to LPA, which typically
results in neurite collapse during development. Sequence homology between PRGs
suggests other members may play a similar role as PRG-1 during development.
PRG-3 is another member of the LPP subfamily that shows high sequence
homology to PRG-1 and 2. PRG-3 is highly regulated during development and is
expressed as early as E16. PRG-3 is expressed in the hippocampus, but expression
levels are lowered throughout development (Wang and Molnár 2005). Unlike PRG-1,
PRG-3 does not have brain-specific expression and is also found in the liver, kidney, and
testis (Savaskan et al. 2004). Overexpression of PRG-3 promotes filopodia formation
and neurite shaft protrusion, possibly through the ROCK and Rho pathways (Broggini et
al. 2016; Velmans et al. 2013). Additionally, PRG-3 shRNA knockdown or knockout
experiments have reduced neurite protrusion (Velmans et al. 2013). It has been shown
that PRG-3 knockouts lead to morphological changes within neuronal cell lines. Although
PRG-3 expressing N1E-115 cells show no LPA ectophosphatase activity (Savaskan et
al. 2004), overexpression of PRG-3 in cortical neurons after injury promotes axonal
regeneration (Fink et al. 2017). This functionality could be attributed to the C-terminal tail
of the PRGs located on the cytoplasmic side of the membrane. The cytoplasmic tail
position is suggestive of a regulatory or signal transduction domain. PRG-3 has a short
C-terminal tail compared to the long 400aa tail of PRG-1.
PRG-5, the last of the PRG family to be characterized, it has a short C-terminal
domain that interacts with various phosphorylated phosphatidylinositols such as the
LPA-precursor PA (Coiro et al. 2014). Moreover, PRG-5 has been found to attenuate
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LPA-induced neurite retraction in N1E-115 cells (Broggini et al. 2010; Coiro et al. 2014).
Thus, PRG-5's observed interactions with phosphorylated lipids suggest that the Cterminal tails on PRGs play a crucial role in their lipid binding and axonal development.
Overexpression studies of PRG-5 in neurons reveal filopodia formation and neurite
growth (Broggini et al. 2010; Coiro et al. 2014). Equally important, PRG-5 shows
differential expression throughout development in the hippocampus and spinal cord
(Broggini et al. 2010).
PRG-2, like PRG-1, has a long 400 amino acid C-terminal domain. Additionally,
PRG-2 has similar ectophosphatase domains to PRG-1 (Cheng et al. 2016). PRG-2 was
shown to be involved with LPA-induced thalamic axonal guidance in mice, where LPA
production was reduced by inhibiting autotaxin (an LPA synthesizing enzyme) which
resulted in aberrant axonal extensions. Moreover, when grown on an LPA-rich substrate,
PRG-2-/- murine thalamic axons are not repelled, allowing them to enter LPA-rich zones.
PRG proteins appear to function in an LPA-dependent manner as possible LPAeffectors, sensors, or scavengers in controlling axonal growth and navigation (Fink et al.
2017; Strauss and Bräuer 2013). There are several studies on PRG 1,3 and 5; however,
there remains a dearth of information on PRG-2 and 4. A complete understanding of the
functional mechanisms behind the lipid metabolism observed in PRGs could provide
potential therapeutic strategies for neuropathological diseases. Based on these findings,
I developed my thesis to investigate the role of PRG-2 and LPA-mediated signaling in
the Gallus gallus visual system during neuronal development, using CRISPR-Cas9
receptor knockdown and GFP/PRG-2 plasmid overexpression.
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Chapter Two
Materials and Methods
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Determining PRG-2 Expression
To establish which PRG genes are expressed in the developing chicken eye, I
used the oneTaq HotStart PCR kit. PCR was performed on RT+ and RT- samples
compared to GAPDH for controls. To obtain RNA, 12 fertilized chicken eggs (provided
by Tyson Foods) were incubated at 39°C until E6. Chicken embryos were then
dissected, and their retinas were removed. E6 retinal RNA was obtained using the
TRIzolTM Reagent isolation method. Two sets of primers for the chicken homologs of
PRG-1,2,3,4, and 5 were designed using National Center for Biotechnology Information
(NCBI’s) Primer-BLAST tool (http://www.ncbi.nlm.nih.gov/tools/primer-blast/) (Table 1).
To quantify PRG-2 expression in the chicken retina and determine a
developmental expression pattern, the retinas from E6, E7, E8, E10, and E12 chick
embryos were dissected. RNA was isolated using the TRIzolTM Reagent isolation
method. PCR was then performed on RT+ and RT- samples compared to GAPDH for
controls.
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Name
PRG3-1 Forward
PRG3-1 Reverse

Sequence
GTCGCCTTGTTTCTGGGGATA
TGCTGCCAATCTTCCATCTCA

Product Length
198
198

PRG3-2 Forward
PRG3-2 Reverse
PRG2-1 Forward
PRG2-1 Reverse
PRG2-2 Forward
PRG2-2 Reverse
PRG1-1 Forward
PRG1-1 Reverse
PRG1-2 Forward
PRG1-2 Reverse

GTGGAGGTGATTGAAAAGGCG
TGGACAACACATATCCCCAGAAA
CGTAAGGTTTGTGGGTGTCC
GACACATAGACAGCGGCGAA
ACTTCTTGGAGCTCACCGAC
AAGACGTGGACACCCACAAA
TCTACTTCGTAGAGTTGCCAAT
GGCCTCTGTTCCAATCCCAT
TTCTACTTCGTAGAGTTGCCAAT
TTGGCCTCTGTTCCAATCCC

275
275
267
267
193
193
269
269
272
272

PRG5-1 Forward
PRG5-1 Reverse
PRG5-2 Forward
PRG5-2 Reverse

GGCCTCAGAGAGTGGTTGTG
GTGTCGCTTAGTTTCTGTCATTC
TTCCCGCTGATGACCACTTC
GTGTCGCTTAGTTTCTGTCATTCA

187
187
261
261

Table 1: Primer sets for PRG-1,2,3,5 designed using NCBI Primer Blast. Each PRG had
two sets of primers both the forward and reverse sequences are shown along with the
associated product length.
gRNA Design
I designed six different gRNAs for Gallus gallus PRG-2 (aka PLPPR3) using the
Benchling CRISPR gRNA design website (https://www.benchling.com/crispr/) (Table 2).
From the gRNA sequences recommended by the Benchling website, I added my
selected measures for the gRNAs based on a previous paper (Gandhi et al. 2017). First,
I selected a sequence of 19 to 20 nucleotides in length adjacent to an NGG proto-spacer
motif (PAM) sequence. Next, I ensured my gRNA would result in a cut between an exon
and intron boundary. Oligonucleotides were ordered from Eurofin Genomics as forward
and reverse primers and annealed to produce double-stranded oligos (Table 2). The
annealed oligos were ligated into the U6.3>gRNA.fte vector (Gandhi et al. 2017;
addgene: 99139) at the 5' and 3' overhangs. The U6.3>gRNA.fte vector was provided to
our lab by Marianne Bronner.
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PRG

Position

gRNA Sequence

PAM

PRG2-1

Exon-1

CAGGAGAGTCATGCTGTCCT

TGG

PRG2-2

Intron-2

TGCCCCCCAGCTGCCCATCG

TGG

PRG2-3

Exon-3

GCGCCGCACCGTAAGGTTTG

TGG

PRG2-4

Exon-4

AGACAGGATGGCGTGCTTGT

CGG

PRG2-5

Exon-5

ACTCACCGACACATAGACAG

CGG

PRG2-6

Exon-2

CGCGCTCTCCATGCCCTACG

TGG

Table 2: Six different guide RNAs (gRNAs) for Gallus gallus PRG-2 (aka PLPPR3) were
made using the Benchling CRISPR gRNA design website. Each sequence is a singlestranded DNA oligonucleotide with overhangs specifically designed to be used for
ligation into the U6.3>gRNA.fte. vector targeting PRG-2. The associated PAM sequence
and position dictates the general location of the cut that Cas9 will make and which intron
or exon boundary the cut should be made.
The plasmid U6.3>gRNA.fte; addgene: 99139 was linearized with Bsal-HF with
either 5'-GGAT-3' or 3'-CAAA-5' overhangs which allowed me to clone my annealed
oligos into my vector. The ligation reaction was incubated for 20 minutes at room
temperature (25-27°C). After incubation, high-efficiency 5-alpha Competent E. coli
(DH5a; New England BioLabs) were transformed with the ligated gRNA vector. SOC
Medium was used for the transformation procedure. E. coli cells were spread on prewarmed LB agar plates containing 100 ug/ml carbenicillin. The ligation reaction
produced over a hundred colonies in total.
gRNA Isolations
To screen for successful inserts, I isolated plasmid DNA using the Zymo research
miniprep plasmid DNA purification kit. The transformed E. coli were left to grow in LB
medium overnight. To determine if my gRNA ligated into the U6.3 vector, I PCRamplified using U6 sequencing primers (5'-ATCGGCTAAGCGGGCCTAAG-3’) with
gRNA reverse primers. I confirmed that five of the gRNAs oligos were cloned into the
U6.3>gRNA.fte vector through sequencing; gRNA6 was not successfully cloned. I stored
my cloned gRNA vectors at -20°C.
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Cell Culture, Transfection of DF1-Cas9 Cells
An immortalized chicken DF-1 fibroblast cell line expressing Cas9 (DF1-Cas9;
Gandhi et al. 2017) was previously obtained. DF1-Cas9 cells were cultured at 37°C in
5% CO2 in DMEM (Hyclone) supplemented with 10% fetal bovine serum (Gibco) and
penicillin/streptomycin (Hyclone). To test gRNAs, DF1-Cas9 cells were transfected with
each of the previously cloned gRNAs and tdTomato. DF1-Cas9 cells were seeded to
achieve 80% confluency by the day of transfection. I used FuGene-HD reagent
(Promega) for the transfections. The plasmid DNA was added to a mixture with the
FuGene-HD reagent in a 3:1 ratio of FuGene-HD to plasmid DNA. I incubated my
mixture for 10 minutes and added it to my DF-1/Cas9 cells. The cells grew for 2 days
before analyzing my transfected cells under with fluorescence microscopy.
Cell Sorting, DNA Isolation
For analysis of transfected cell DNA via cell sorting, DF1-Cas9 cells were washed
once with PBS and then harvested from their culture dish using Trypsin for 5 minutes at
37°C, then centrifugated for 5 minutes at 1500rpm. Cells were resuspended in
phosphate-buffered saline (PBS) (Gibco) with 0.5% fetal bovine serum (FBS) and 0.1
mM EDTA at 400,000 cells/mL (according to Nanocellect WOLFsorter). The cells were
then filtered (50 µm) to remove aggregates and then stored on ice. Cell sorting was done
following the Nanocellect WOLFsorter manufacturer protocol. Each of the
RNA/tdTomato transfected cells in 1.5 ml Eppendorf tubes were left on ice before DNA
isolation.
Sorted cells were pelleted via centrifugation for 10 minutes at 3600 rpm, and the
supernatant was removed. The pelleted tdTomato-positive cells were resuspended in a
cell lysis solution (100 mM TrisCI, pH 8, 50 mM EDTA, 1% (w/v) sodium dodecyl
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sulfate) until viscous. The cell lysate was centrifugated at max speed for 3 minutes using
an Eppendorf tube, and the supernatant was transferred into a 1.5 ml Eppendorf tube
containing 600 µl of isopropanol, and mixed, followed by max centrifugation in an
Eppendorf centrifuge for 1 minute at room temperature. The supernatant was removed,
and the pellet was washed with 70% EtOH, followed by max centrifugation for 1 minute.
The supernatant was removed, and the DNA pellet was air-dried. DNA was resuspended
in nuclease-free H2O and incubated overnight at room temperature to solubilize genomic
DNA before PCR amplification.
PCR-amplification of Mutation
Primers were designed for Phusion High-Fidelity DNA Polymerase PCR using the
PRG-2 genomic sequence found using NCBI's Primer-BLAST
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/). Using the following criteria: 1) the
primers must have a Tm>55°C, 2) their length be between 18 and 22 base pairs, and 3)
they had a 45 to 60% GC content. Table 3 shows the forward and reverse primer target
locus and the expected amplicon of PCR production for each gRNA.
Name
PRG2-1 Forward
PRG2-1 Reverse
PRG2-3 Forward

Sequence
CATGATCTCCCCGAAGGAC
AGGGCTCAATGCCATCC
CAGATCATGCTCGGGGAG

Product Length
222
222
215

PRG2-3 Reverse
PRG2-4/5 Forward
PRG2-4/5 Reverse
PRG2-7 Forward

ACAGAGGGGTCGGGTTC
CCAACCCCTACATCACGC
GAGTTGAAGTACATCTGGAG
TCTTCGCCTTCGCCATC

215
285
285
213

PRG2-7 Reverse

TGGTACGCCTGTGGGTA

213

Table 3: Design of forward and reverse primers for Phusion PCR-amplification over PRG
2-1,3,4,5,7 mutated genomic DNA regions of transfected DF-1 tdTomato-positive cells.
Each primer should amplify the region mutated by the CRISPR system.
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Mutation Validation
Transfected and sorted cell DNA was used for PCR amplification using Phusion
High Fidelity with PRG-2 Phusion primers (Table 3). Amplicons were then gel purified
(Zymo), and TA cloned into CloneJET PCR Cloning Kit (ThermoFisher) was transformed
into high-efficiency 5-alpha Competent E. coli (DH5a; New England BioLabs) E. coli cells
were spread on pre-warmed LB agar plates containing 50 µg/ml carbenicillin. The
cloning reaction produced over a hundred colonies in total. Fifteen clones were selected
for each gRNA, plasmid prep by miniprep, and sent off for sequencing at Eurofins
Genomics. Sequences were compared using Clustal Omega Sequence alignment
(https://www.ebi.ac.uk/Tools/msa/clustalo/).
Ex ovo Chicken Embryo Culture, Injection, and Electroporation Optimization
Fertilized chicken eggs were obtained from Tyson Farms. Eggs were incubated at
39°C with rocking and humidity for 2 days until experimental procedures. Solo plastic
cups were weighted with 35 mL of sterilized distilled H2O before a 4 cm-deep plastic
hammock made of Saran brand plastic wrap was made and secured with a rubber band.
Cup lids were given a single puncture for airflow, and the cups and lids were UV
sterilized for 45 minutes. On embryonic day two (E2), embryos were ex ovo cultured in
the plastic cups by cutting an opening to carefully transfer the entire contents of the eggs
into ex ovo cups and placed into a 39°C incubator with water for humidity until E2. At E3,
a 2:1 solution of water and 2627.5ng/ul tdTomato plasmid (addgene:30530), along with
0.05% Fast Green (for visualization), was injected into the subretinal space of the
cupped embryo and electroporated using a BTX ECM 830 Electroporation Generator
System that was set to 5 pulses of 15V for 50 ms with 950 ms intervals as previously
described (Islam et al. 2012). Electroporated embryos were placed back in the incubator
and allowed to develop until retinal dissections were done at E6.
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Retinas were dissected by removing the iris to expose the retina from
electroporated embryos on embryonic day 6 (Hamburger and Hamilton stages 28-29)
under a fluorescence stereoscope. Dissected retinas were then imaged using a
fluorescent microscope.
Overexpression of GFP-PRG-2 Construct
DF-1 cells were cultured at 37°C in 5% CO2 in DMEM (Hyclone) supplemented
with 10% fetal bovine serum (Gibco) and penicillin/streptomycin (Hyclone). DF-1 cells
were transfected with either the GFP plasmid or my PRG2-Mouse in pcDNA3.1(+)-EGFP
fusion protein plasmids. This plasmid was designed to express mouse PRG-2 and GFP
fusion protein for visualization. DF-1 cells were seeded to achieve 80% confluency by
the day of transfection. I used a lipid-based FuGene-HD reagent (Promega) for
transfection. The DNA was added to a mixture with the FuGene-HD reagent in a 3:1
ratio of FuGene-HID to plasmid DNA. I incubated my mixture for 10 minutes and added it
to my DF-1 cells. The next day I changed the media on the cells and allowed them to
grow for 2 days before analyzing the transfected cells under confocal fluorescence
microscopy.
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Chapter 3
Results
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Expression
PRGs are tightly regulated proteins expressed throughout different phases of
brain development (Brauer 2008; Yu et al. 2015). Their differential expression suggests
roles in neuronal development. Research on PRG has mainly focused on glutamatergic,
hippocampal, and cortical neurons of mice, rats, and humans. However, their expression
and localization patterns suggest roles in other brain regions and cell types (Fuchs et al.
2022). The primary goal of this research is to determine the function of PRG-2 in the
neuronal development of the visual system and its interaction with LPA. To investigate
this question, I first determined the expression of PRGs in the embryonic chicken eye
using RT-PCR. Two sets of primers for the chicken homologs of PRG-1,2,3,4, and 5
were designed using National Center for Biotechnology Information (NCBI) PrimerBLAST tool (http://www.ncbi.nlm.nih.gov/tools/primer-blast/) (Table 1). PCR was
performed on RT+ and RT- samples of the E6 retina using designed primers and
compared to GAPDH as a control (Figure 2). I found that PRG-2,3 and 1 are expressed
in the E6 chicken retina. PRG-5, however, was not expressed in the retina; but is
expressed in the brain (data not shown). This suggested that PRGs possibly play a role
in the retinal development of chickens. This also ensured that chickens are a good
model organism to study PRG functions.
During Rat early developmental stages at embryonic (E) days E14-E16, PRG-3
mRNA was detected in the subventricular zone, ventricular zone, the cortical plate, and
the hippocampal anlage (Savaskan et al. 2004; Wang and Molnár 2005). In situ
hybridization and immunoblotting analyses identified PRG-2 expression from E14.5
onwards in thalamic and cortical brain regions (Cheng et al. 2016) with increasing mRNA
and protein expression levels from E16 until early postnatal stages (Brosig et al. 2019).
To quantify PRG-2 expression in the chicken retina and determine a developmental
expression pattern, the retinas from E6, E7, E8, E10, and E12 chick embryos were
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dissected, and RNA was isolated. PCR was then performed on RT+ and RT- samples. I
found PRG-2 to be expressed throughout the development of the chicken retina,
suggesting it has a potential role during similar developmental time periods for other
organisms (Figure 3).
System to Mutate PRG-2 Using CRISPR
PRG-2 is essential for guiding thalamocortical axonal projections into the
intermediate zone during development (Cheng et al. 2016). In this case, guidance
depended on LPA and protein-protein interactions between PRG-2 and radixin.
Interestingly, adult PRG-2 KO mice exhibited dampened neuronal activity at the cortical
projection site and subsequent impaired local information processing shown by whiskerdependent sensory discrimination (Cheng et al. 2016). PRG proteins, specifically PRG2, appear to function in an LPA-dependent manner as possible LPA-effectors, sensors,
or scavengers in controlling axonal growth and navigation (Fink et al. 2017; Strauss and
Bräuer 2013). Therefore, I hypothesized that RGC growth cones with a mutated PRG-2
will have reduced collapse when exposed to LPA at various concentrations. I designed 6
different gRNAs for Gallus gallus PRG-2 (aka PLPPR3) to test this hypothesis using the
Benchling CRISPR gRNA design website (Table 2). I designed each gRNA to cut at an
intron-exon boundary on the PRG-2 DNA sequence (Figure 4). After Cas9 made the cut
and cell repair occurred, the resulting PRG-2 protein will hypothetically have noncoding
(intronic) regions in the final product leading to loss of function.
CRISPR, however, is not 100% effective; for various reasons one gRNA could
make a cut and induce a mutation 9 out of 10 times (90% mutation rate), and another
could mutate 4 out of 10 or 40%. In order to pick the gRNA with the highest mutation
rate, I first screened each of my gRNA by transfecting it along with tdTomato into DF-1
Cas9 cells. I then sorted the transfected cells to isolate the tdTomato-positive population.
Afterward, I harvested the DNA of the tdTomato-positive cells and sent them for
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sequence to identify the mutation rate. The gRNA cloning process for CRISPR resulted
in a single gRNA with a 40% mutational rate and some others with no mutation (Table
4). To generate these mutation rates, 15 colonies from each transformation was
collected and sent for sequencing. As stated before, a 40% mutation rate is too low to
produce accurate results during experimentation. Despite the increasing specificity of
CRISPR-Cas9 technology, some critical considerations still require comprehensive
studies. Efforts to increase specificity have been conducted to improve RNA design
(Gandhi et al. 2017)
To enhance the injection efficiency to deliver a CRISPR construct into the chick
retina, I optimized the procedure. My in vitro data must have a statistically appropriate
number of growth cones to analyze in order to compare mutated RGC growth cones
against the control. I used the method of electroporation (i.e., an electric current is used
to force the negatively charged DNA into the cells) to deliver the DNA after I had
successfully microinjected plasmids into the subretinal space at E3 of development. To
assess my co-electroporation efficiency, I then dissected the retina of the injected
embryo on E6 and viewed them under a fluorescent microscope. The E6 embryo retina
successfully took up my tdTomato injection solution (Figure 5). In order to achieve these
results, I faced several obstacles that required optimization. The first being chicken
viability which is naturally affected by age of the eggs before initial incubations as well as
the cupping and injection procedure. Optimizations for both variables were done through
multiple experiments.
System for Overexpression of PRG-2
Another way to determine the function of PRG-2 is by inducing its overexpression. Most studies have utilized overexpression or stable cell lines to study PRG
localization in different cellular membrane systems (Fuchs et al. 2022). Interestingly,
overexpression of different PRG family members enhances their plasma membrane

21

localization (Brosig et al. 2019; Yu et al. 2015). I hypothesized that RGC growth cones
with overexpressed PRG-2/GFP construct would be more sensitive to LPA, and there
would be increased collapse when exposed to lower concentrations. To test this
hypothesis, I validated the overexpressed PRG-2 first in DF-1 cells to ensure the
construct could be taken up. Using the PRG-2/GFP construct, I transfected these
chicken fibroblast cells to confirm that my PRG-2/GFP fusion construct could be
expressed and used confocal imaging to visualize the expression in the cells (Figure 6).
After confirmation of my PRG-2/GFP construct expression, I proceeded to ex ovo
cupping and injections. Unfortunately, injections and electroporation of PRG-2/GFP
construct into the chicken retina depend on the embryo's viability after cupping and the
injection procedure. For instance, initial incubations before cupping started with a
sample size of 60 embryos and after cupping this sample size was reduced to 50.
Injections likewise reduced this sample size to an average of 25. The number of
surviving embryos further decreased to 10 during development from E3-E6, affected by
such things as mold or irreparable damage from injections. Although this experiment
was run multiple times because of viability issues, I did not collect growth cone collapse
data.
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500bp

Figure 2: RT-PCR of E6 chicken retina using two sets of primers designed to detect
PRG-2, and 3, mRNA and one set of primers for PRG-1, and 5. Bands seen in each lane
left of the 100bp ladder correspond to the different PRGs. For a control, GAPDH (Control
Lane) was used. A negative control without reverse transcriptase (RT) was also used
(data not shown) and no bands were observed. Expected band sizes from left to right
PRG-2: 272bp, 298bp, PRG-3:198bp, 275bp, PRG-1: 272bp, 269bp, PRG-5: 261bp.
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E6 E7 E8 E10 E12

267bp
Figure 3: RT-PCR of the chicken retina from embryonic days E6, E7, E8, E10, E12 using
PRG-2: 267bp specific primers and a 100bp ladder (not shown). PRG-2 is expressed
throughout the chicken's development, as seen by the bands in each lane. For negative
control, samples with no reverse transcriptase were used (data not shown).

Figure 4: PRG-2 NCBI gene product map with Intron and Exon positions of designed
gRNAs. PRG-2 (green line) has 6 Exons (green rectangles) and 5 introns (green space
between the rectangles). The colored boxes show where each gRNA was designed to
cut along the PRG-2 product.
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Table 4: Clones selected from gRNA 1,3,4, plasmid transformation, and sent for
sequencing at Eurofins Genomics. The mutation rate that resulted from the CRISPR
construct gRNA 4 had only 4 out of 10 of the samples mutated. The other gRNA shown
(3 and 1) had no mutations.
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Figure 5: A fluorescent image of dissected E6 embryo retina that has successfully taken
up my tdTomato injection solution from the optimization of ex ovo embryo cupping and
injections. The dots are the labeled cell bodies and tracks are axons extending to form
an optic nerve.

Figure 6: Using my PRG2-Mouse in pcDNA3.1(+)-EGFP fusion protein plasmids, DF-1
chicken fibroblast cells were transfected. To confirm that my GFP/PRG-2 fusion
construct could be expressed transfected DF-1 cells (green shapes) were imaged using
a confocal microscope.
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Chapter Four
Discussion
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System for Knockdown Of PRG-2 using CRISPR
PRG-2, like PRG-1, has a long 400 amino acid C-terminal domain. Additionally,
PRG-2 has similar ectophosphatase domains to PRG-1 (Cheng et al. 2016). PRG-2 was
shown to be involved with LPA-induced thalamic axonal guidance in mice, where LPA
production was reduced by inhibiting autotaxin (an LPA synthesizing enzyme) which
resulted in aberrant axonal extensions. Moreover, when grown on an LPA-rich substrate,
PRG-2-/- murine thalamic axons are not repelled, allowing them to enter LPA-rich zones.
PRG proteins appear to function in an LPA-dependent manner as possible LPAeffectors, sensors, or scavengers in controlling axonal growth and navigation (Fink et al.
2017; Strauss and Bräuer 2013). To investigate whether or not LPA and PRG-2 play a
similar role in RGC development, I hypothesized that RGC growth cones with a mutated
PRG-2 will have reduced collapse when exposed to LPA at various concentrations. To
test this, I designed six guide RNAs (gRNA) to PRG-2 for mutation with CRISPR-Cas9. I
designed each gRNA to cut at an intron-exon boundary within the PRG-2 DNA
sequence. I did this hoping that after Cas9 made the cut and cell repair occurred, the
resulting PRG-2 protein would hypothetically have noncoding (intronic) regions in the
final product leading to loss of function. However, the CRISPR-Cas9 system is not 100%
effective. For instance, one gRNA could cut and induce a mutation only 4 out of 10
times or 40% and another at a higher rate. Because I co-electroporate with another
plasmid, tdTomato, I could get explants that took up the tdTomato but do not have a
mutation. In other words, neurites would look like they are generally behaving with no
mutation even if they have taken up the florescent plasmid. However, following the
design criteria did not result in mutations that could be used in this experiment. The
gRNA cloning process for CRISPR resulted in a single gRNA with a 40% mutational rate
and some with no mutations.

28

I have already determined the developmental expression of PRGs in the
embryonic chicken eye using RT-PCR (Figure 2 and 3) and developed the tools to
mutate PRG-2 in the developing chicken eye using CRISPR-Cas9 technology (Table 2).
Using this data, a continuation of this project would first consist of optimizing the
CRISPR constructs and revalidating their mutation rates. Using a validated construct to
mutate the PRG-2 receptor and performing a growth cone collapse assay could produce
a multitude of results. A typical growth cone collapse assay consists of dissected retinal
ganglion cells explants being treated with media control or LPA at 1µM, 100nM, or 10nM
concentrations, incubated for 10 minutes in a 37°C, 5% CO2 incubator, then fixed.
Growth cone collapse is quantified by counting isolated growth cones attached to
neurites emanating from the explant using an inverted florescent microscope. They can
then be categorized as collapsed or not and the percent collapsed can be calculated as
previously done in our lab (Fincher et al. 2014). Figure 7 shows a typical growth cone
collapse assay. However, RGC growth cones with a mutated PRG-2 may have reduced
collapse when exposed to LPA, as I hypothesized (Figure 8). Alternatively, instead of
seeing a attenuation for growth cone collapse, one could see a partial reduction in the
number of growth cone collapses, suggesting PRG-2 modulates growth cone response
to LPA but does not entirely control it (Figure 9). The neurite outgrowth activity of PRG
likely involves LPA and other extracellular growth inhibition signals and associated
receptors (Fuchs et al. 2022). In the extreme, we could see a complete attenuation of
growth cone collapse (Figure 10).
System for Overexpression
Multiple studies have suggested that PRG 1,4, and 5 following overexpression in
neuronal cell lines result in aberrant LPA downstream signaling and its effects on cellular
morphology and neurite retraction (Agbaegbu Iweka et al. 2021; Bräuer et al. 2003;
Broggini et al. 2016). The proposed mechanisms for these aberrant signals involve the
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engagement of RhoA in inactive complexes with RhoGDI following the overexpression of
PRG-1. Similarly, overexpression of PRG-5 reduces LPA-activated RhoA in cell lines.
Thus, a pattern emerges that PRGs may function as a fine-tuning device for LPAinduced RhoA activity and its biological effects (Fuchs 2022). For these reasons, I
hypothesized that RGC growth cones with overexpressed PRG-2/GFP construct would
be more sensitive to LPA. If exposed to this axon guidance molecule during an assay,
there would be increased growth cone collapse at lower concentrations (Figure 11).
To test this hypothesis, I had to establish the overexpression of PRG-2 first in
DF-1 cells to ensure the construct could be taken up and expressed. Using the PRG2/GFP construct, I transfected chicken fibroblast cells and confirmed overexpression by
confocal imaging. This established that my mouse construct could be expressed in
chickens. After confirming the expression by confocal imaging, I proceeded to retinal
injections. Unfortunately, injections and electroporation of the PRG-2/GFP construct into
the chicken retina depend on the embryo’s viability after cupping and the injection
procedure. Ex ovo cupping exposes the developing embryo to a host of variables that
often result in the death of the developing embryo. Compounding this is the natural
chicken viability. Not all embryos will develop to the stages needed to perform
experiments. Because of viability issues, I did not collect growth cone collapse data.
Further data in the form of western blotting would also be needed to ensure the entire
fusion protein is being expressed and not just GFP. Although this has been partially
done through the confocal imaging; cells sometimes process protein-protein constructs
in different ways. For instance, the PRG-2 part of the construct could be cleaved off
during protein processing resulting in expression of only GFP and not PRG-2. After
confirmation, injections and electroporation could be performed to interrogate the
functions of PRG-2.
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Overall, there are still some important considerations when investigating PRG-2
that require comprehensive studies; currently we lack the molecular insight needed to
understand the functional implications of the PRG and LPA signaling interactions during
development. Ongoing studies of PRG KO mice and PRG polymorphisms in humans
suggest a dominant role of PRG deficiency for several CNS diseases. Moreover, there
are several lines of evidence suggesting PRGs may affect the regeneration processes
following CNS injury (Fuchs et al. 2022). Elucidating the roles of PRGs in CNS disease
could result in the emergence of PRG as a novel pharmacological target.

Figure 7: A typical growth cone collapse response to LPA is shown by the solid black
line and S1P (another guidance cue) by the dashed line. At the lower concentration,
there is minor collapse but as the concentration increases, so does the growth cone
collapse (Fincher et al. 2014).
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Figure 8: For my first hypothesis, if PRG-2 interacted with LPA normally resulting in a
collapse response, when PRG-2 is mutated, I expect the growth cone collapse to be
less, even in the higher LPA concentrations (red line).

Figure 9: For my alternative hypothesis, if PRG-2 was not the only receptor that
modulates response to LPA, I would expect that instead of seeing a complete
attenuation for growth cone collapse, one could see a partial reduction in the number of
growth cone collapses, suggesting PRG-2 modulates growth cone response to LPA but
does not entirely control them (bold blue line).
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Figure 10: The orange line is an extreme case in which I hypothesized that mutation of
PRG-2 through CRISPR could result in a complete attenuation of growth cone collapse.

Figure 11: If PRG-2 was overexpressed in RGCs then the LPA response would
increase. Thus, I hypothesized that RGC growth cones with overexpressed PRG-2/GFP
construct would be more sensitive to LPA (green line). If exposed to this axon guidance
molecule during an assay, there would be increased growth collapse at lower
concentrations.
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